title: 2-18F-Fluoroethanol Is a PET Reporter of Solid Tumor Perfusion.
abstract: Solid tumor perfusion is a proven variable of interest for predicting cancer aggression and response to therapy. Current methods for noninvasively imaging tumor perfusion with PET are limited by restricted accessibility and short half-lives of perfusion radiotracers. This study presents 2-18F-fluoroethanol (2-18F-FEtOH) as a perfusion reporter that can distinguish between tumors of varying perfusion levels and can be applied to screening drugs that modify tumor perfusion.Methods:Uptake of 2-18F-FEtOH in 4T1 and 67NR murine mammary carcinoma tumors grown in mice was measured using ex vivo radiography as well as static and dynamic PET imaging. 2-18F-FEtOH uptake was directly compared with the14C-iodoantipyrine perfusion reporter, and the perfusion-modifying drugs nicotinamide, pentoxifylline, and hydralazine were used to manipulate tumor perfusion before 2-18F-FEtOH quantification.Results:Uptake of 2-18F-FEtOH in 4T1 and 67NR tumors was consistent with known perfusion differences within and between these tumors. 2-18F-FEtOH uptake corresponded well with14C-iodoantipyrine and reflected the tumor perfusion-modifying effects of each drug.Conclusion:2-18F-FEtOH is a novel18F-based radiotracer for investigating tumor perfusion with PET imaging. Quantification of 2-18F-FEtOH uptake can be used to distinguish between tumors of varying perfusion and to screen the efficacy of blood flow-modifying drugs for use as adjuvants to existing cancer therapies.
authors.affiliation: Integrative Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.|Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; and.
authors.forename: Brennan J
authors.initials: BJ
authors.lastname: Wadsworth
authors.affiliation: Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Jinhe
authors.initials: J
authors.lastname: Pan
authors.affiliation: Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Iulia
authors.initials: I
authors.lastname: Dude
authors.affiliation: Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Nadine
authors.initials: N
authors.lastname: Colpo
authors.affiliation: Integrative Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.|Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; and.
authors.forename: Momir
authors.initials: M
authors.lastname: Bosiljcic
authors.affiliation: Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Kuo-Shyan
authors.initials: KS
authors.lastname: Lin
authors.affiliation: Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Francois
authors.initials: F
authors.lastname: Benard
authors.affiliation: Integrative Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada kbennewi@bccrc.ca.|Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; and.
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Bennewith
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003937:Diagnosis, Differential; D000431:Ethanol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging* / Q000209:etiology / Q000378:metabolism*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014018:Tissue Distribution
chemical_list: D019275:Radiopharmaceuticals; D000431:Ethanol; C001236:2-fluoroethanol
keywords: 2-18F-fluoroethanol; hydralazine; nicotinamide; positron emission tomography; tumor perfusion